+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Somatostatin Analogue Drug Market 2020-2026

  • ID: 5148078
  • Report
  • July 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Camurus AB
  • Chiasma, Inc.
  • Eli Lilly & Co.
  • Hutchison MediTech, Ltd.
  • Ipsen Group
  • Midatech Pharma Plc
Global Somatostatin Analogue Drug Market Size, Share & Trends Analysis Report by Type (Octreotide, Lanreotide, Pasireotide), by Indication (Acromegaly, Neuroendocrine Tumor (NET), Others) Forecast Period (2020-2026).

The somatostatin analogue drug market is anticipated to showcase a considerable growth rate during the forecast period. The continuous rise in the number of government initiatives, grants, and funding by various international organizations is expected to promote the growth of the market across the globe. However, due to lack of awareness huge number of people suffering from Neuroendocrine Tumor (NET) remains undiagnosed which is anticipated to be a key factor that may restrain the growth of the global market across the globe.

The somatostatin analogue drug market is segmented on the basis of type and indication. Based on the type, the market is segmented into octreotide, lanreotide, and pasireotide. Octreotide is anticipated to hold major market share based on type. The growing adoption of octreotide in the treatment of acromegaly and NET owing to its offered benefits is a key factor contributing to the high share of the market segment. Based on indication, the market is segmented into acromegaly, NET, and others.

Geographically, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America is anticipated to hold a considerable market share in the somatostatin analog market due to the high prevalence of NET and acromegaly in the region. Asia-Pacific is the fastest-growing region in the somatostatin analog market. The increasing rate of NET diagnosis along with rising per capita income in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.

Camurus AB, Chiasma, Inc., Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Tarveda Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and so on are the prominent players operating in the global somatostatin analogue drug market. These market players are actively adopting various growth strategies such as new product launches and approvals, merger and acquisition, partnerships, collaborations, and strategic agreements among others to thrive in a competitive environment of the global market.

Research Methodology:

The market study of the global somatostatin analogue drug market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Somatostatin Analogue Drug Market Research and Analysis by Type
2. Global Somatostatin Analogue Drug Market Research and Analysis by Indication

The Report Covers:
  • Comprehensive research methodology of the global somatostatin analogue drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global somatostatin analogue drug market.
  • Insights about market determinants which are stimulating the global somatostatin analogue drug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Camurus AB
  • Chiasma, Inc.
  • Eli Lilly & Co.
  • Hutchison MediTech, Ltd.
  • Ipsen Group
  • Midatech Pharma Plc
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Chiasma, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. F. Hoffmann La Roche, Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Boehringer Ingelheim International GmbH
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Novartis AG
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Ipsen Group
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities

5. Market Segmentation
5.1. Global Somatostatin Analogue Drug Market by Type
5.1.1. Octreotide
5.1.2. Lanreotide
5.1.3. Pasireotide
5.2. Global Somatostatin Analogue Drug Market by Indication
5.2.1. Neuroendocrine Tumor (NET)
5.2.2. Acromegaly
5.2.3. Others

6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Boehringer Ingelheim International GmbH
7.2. Camurus AB
7.3. Chiasma, Inc.
7.4. Dauntless Pharmaceuticals, Inc.
7.5. Eli Lilly & Co.
7.6. F. Hoffmann-La Roche, Ltd.
7.7. Hutchison MediTech, Ltd.
7.8. Ipsen Group
7.9. Midatech Pharma Plc
7.10. Novartis AG
7.11. Peptron, Inc
7.12. Pfizer, Inc.
7.13. Sun Pharmaceutical Industries, Ltd.
7.14. Tarveda Therapeutics, Inc.
7.15. Teva Pharmaceutical Industries, Ltd.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Boehringer Ingelheim International GmbH
  • Camurus AB
  • Chiasma, Inc.
  • Dauntless Pharmaceuticals, Inc.
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche, Ltd.
  • Hutchison MediTech, Ltd.
  • Ipsen Group
  • Midatech Pharma Plc
  • Novartis AG
  • Peptron, Inc
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries, Ltd.
  • Tarveda Therapeutics, Inc.
  • Teva Pharmaceutical Industries, Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll